title: Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review.
abstract: BACKGROUND
  Denosumab, an anti-resorptive agent, IgG2 monoclonal antibody for human Receptor activator of nuclear factor-kappa B ligand (RANKL), has been related to the occurrence of osteonecrosis of the jaws. Thus, the aim of this study was to review the literature from clinical case reports, regarding the type of patient and the therapeutic approach used for osteonecrosis of the jaws induced by chronic use of Denosumab.
  
  
  METHODS
  For this, a literature review was performed on PubMed, Medline and Cochrane databases, using the keywords "Denosumab" "anti-RANK ligand" and "Osteonecrosis of jaw". To be included, articles should be a report or a serie of clinical cases, describing patients aged 18 years or over who used denosumab therapy and have received any therapy for ONJ.
  
  
  RESULTS
  Thirteen complete articles were selected for this review, totaling 17 clinical cases. The majority of ONJ cases, patients receiving Denosumab as treatment for osteoporosis and prostate cancer therapy. In most cases, patients affected by ONJ were women aged 60 or over and posterior mandible area was the main site of involvement. Diabetes pre-treatment with bisphosphonates and exodontia were the most often risk factors related to the occurrence of this condition. Systemic and local antibiotic therapy with or without surgical debridement was the most used treatment for ONJ resolution.
  
  
  CONCLUSIONS
  It is concluded that the highest number of ONJ cases caused by the use of anti-RANKL agents occurred in female patients, aged 60 years or older, under treatment for osteoporosis and cancer metastasis, and the most affected region was the mandible posterior.
authors.affiliation: Division of Oral Pathology, Department of Clinical Dentistry, School of Dentistry, Federal University of Ceará, Alexandre Barauna Street, 949, Rodolfo Teofilo, 60430-160, Fortaleza, Ceará, Brazil, camilacdeoliv@gmail.com.
authors.forename: C-C
authors.initials: CC
authors.lastname: de Oliveira
authors.forename: L-A-C
authors.initials: LA
authors.lastname: Brizeno
authors.forename: F-B
authors.initials: FB
authors.lastname: de Sousa
authors.forename: M-R-L
authors.initials: MR
authors.lastname: Mota
authors.forename: A-P-N-N
authors.initials: AP
authors.lastname: Alves
mesh_terms: D000368:Aged; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D000069448:Denosumab / Q000009:adverse effects*; D004164:Diphosphonates; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016328:NF-kappa B; D010020:Osteonecrosis; D053245:RANK Ligand
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D016328:NF-kappa B; D053245:RANK Ligand; D000069448:Denosumab
references.citation: J Prev Med Hyg. 2013 Sep;54(3):138-45
references.pmid: 24783891
references.citation: J Clin Oncol. 2010 Dec 10;28(35):5132-9
references.pmid: 21060033
references.citation: Osteoporos Int. 2014 Jan;25(1):393-5
references.pmid: 23835864
references.citation: J Clin Oncol. 2011 Mar 20;29(9):1125-32
references.pmid: 21343556
references.citation: Eur Urol. 2008 Nov;54(5):1066-72
references.pmid: 18602738
references.citation: Int J Clin Exp Med. 2014 Oct 15;7(10):3707-9
references.pmid: 25419421
references.citation: Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Dec;114(6):671-6
references.pmid: 23159111
references.citation: J Am Dent Assoc. 2012 Sep;143(9):981-4
references.pmid: 22942143
references.citation: Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Jan;119(1):e6-e12
references.pmid: 25174873
references.citation: J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56
references.pmid: 25234529
references.citation: Mayo Clin Proc. 2013 Apr;88(4):418-9
references.pmid: 23541016
references.citation: J Bone Miner Res. 2008 Jun;23(6):826-36
references.pmid: 18558816
references.citation: Am J Clin Oncol. 2012 Aug;35(4):386-92
references.pmid: 22561331
references.citation: Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010 Jul;110(1):46-53
references.pmid: 20452252
references.citation: J Oral Maxillofac Surg. 2014 Apr;72(4):702-16
references.pmid: 24397946
references.citation: N Engl J Med. 2009 Aug 20;361(8):756-65
references.pmid: 19671655
references.citation: Farm Hosp. 2014 May 01;38(3):248-9
references.pmid: 24951910
references.citation: Lancet Oncol. 2013 Aug;14(9):901-8
references.pmid: 23867211
references.citation: J Evid Based Dent Pract. 2012 Sep;12(3 Suppl):233-47
references.pmid: 23040351
references.citation: J Allergy Clin Immunol. 2005 May;115(5):911-9; quiz 920
references.pmid: 15867843
references.citation: J Craniomaxillofac Surg. 2013 Oct;41(7):694-8
references.pmid: 23830772
references.citation: Aten Primaria. 2015 May;47(5):319-20
references.pmid: 25523928
references.citation: Br J Oral Maxillofac Surg. 2010 Apr;48(3):221-3
references.pmid: 19836866
references.citation: J Craniomaxillofac Surg. 2013 Jun;41(4):e65-9
references.pmid: 23265807
references.citation: J Oral Maxillofac Surg. 2010 May;68(5):959-63
references.pmid: 20149510
references.citation: Med Oral Patol Oral Cir Bucal. 2014 Jul 01;19(4):e320-6
references.pmid: 24608203
references.citation: Br J Oral Maxillofac Surg. 2011 Jul;49(5):335-42
references.pmid: 20863603
references.citation: Arq Bras Endocrinol Metabol. 2007 Oct;51(7):1050-7
references.pmid: 18157378
references.citation: Aust Dent J. 2014 Dec;59(4):516-9
references.pmid: 25131835